Extramedullary progression despite a good response in the bone marrow in patients treated with thalidomide for multiple myeloma

Leukemia and Lymphoma

Volumn 42, Issue 4, 2001, Pages 683-687

  Avigdor, A ^a   Raanani, P ^a   Levi, I ^a   Hardan, I ^a   Ben Bassat, I ^a  

^a SHEBA MEDICAL CENTER   (Israel)

Author keywords

Adhesion molecules; Extramedullary plasmacytoma; Multiple myeloma; Resistant; Thalidomide

Indexed keywords

CELL ADHESION MOLECULE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; MELPHALAN; PREDNISONE; THALIDOMIDE; VINCRISTINE;

ADULT; ARTICLE; AUTOTRANSPLANTATION; BONE MARROW; CANCER GROWTH; CASE REPORT; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRANIAL NEUROPATHY; DISEASE RESISTANCE; DRUG RESPONSE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MALE; MULTIPLE MYELOMA; MYELOMA CELL; NEUROLOGIC DISEASE; NOSE MUCOSA; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICIAN; PLASMACYTOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SELLA TURCICA TUMOR; SKIN; SOMNOLENCE; STROMA CELL;

EID: 0034861712     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428190109099330     Document Type: Article

References (17)

1. Antitumor activity of thalidomide in refractory MM
2. Therapy with thalidomide in refractory MM patients - The revival of an old drug
3. Cerebral and meningeal MM after autologous stem cell transplantation. A case report and review of the literature
4. Metastatic cutaneous plasmacytoma: A case report associated with IgA lambda MM and a review of the literature of metastatic cutaneous plasmacytomas associated with MM and primary cutaneous plasmacytomas
5. Extensive extramedullary disease in myeloma. An uncommon variant with features of poor prognosis and dedifferentiation
6. Anaplastic myeloma with massive extramedullary involvement. Report of two cases
7. Graft-versus-myeloma after donor leukocyte infusion: Maintenance of marrow remission but extramedullary relapse with plasmacytomas
8. Discrepancy between serological complete remission and concomitant new bone lytic lesions after infusion of escalating low doses of donor lymphocytes in multiple myeloma: A case report
9. Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma
10. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human MM
11. Thalidomide is an inhibitor of angiogenesis
12. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha
13. Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity
14. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade
15. Thalidomide and the immune system. Simultaneous up- and down-regulation of different integrin receptors on human white blood cells
16. Interaction of tumor and host cells with adhesion and extracellular matrix molecules in the development of MM
17. Leukemia cutis in acute promyelocytic leukemia: Report of three cases after treatment with all-trans retinoic acid